BACKGROUND: Potential treatment-related neurotoxicity and the indolent course of the disease mainly feed the controversy concerning the optimal timing of surgery and radiotherapy in meningioma patients. OBJECT: To quantify the additional negative effects of conventional radiotherapy compared to surgery alone on neurocognitive functioning and health-related quality of life (HRQOL) in patients with WHO grade I meningiomas. METHODS: Neurocognitive functioning and HRQOL (SF36, EORTC-BCM20) were assessed in consecutive patients (1999-2005) with WHO grade I meningiomas at least 1 year after surgical treatment in two centers for brain tumor patients. Subsequently, we selected all patients who underwent surgery and conformal external beam fractioned radiotherapy (n=18) and matched these patients for age, sex, and educational level with the same number of patients who had had surgery only (n=18), as well as with the same number of healthy controls. RESULTS: No significant differences in neurocognitive functioning were found between the two meningioma patient groups; however, even meningioma patients who were treated with surgery only had a significantly lower neurocognitive functioning than healthy controls. Meningioma patients who were treated with surgery and radiotherapy had significantly lower HRQOL scores than meningioma patients who were treated with surgery only, who had HRQOL ratings comparable with healthy controls; these differences, however, disappeared after correction for the duration of disease. CONCLUSIONS: In contrast with conventional thinking, long-term neurocognitive functioning was significantly impaired in our meningioma patients. Additional radiotherapy following surgery, however, does not have additional deleterious effects on neurocognitive outcome in these patients.
BACKGROUND: Potential treatment-related neurotoxicity and the indolent course of the disease mainly feed the controversy concerning the optimal timing of surgery and radiotherapy in meningiomapatients. OBJECT: To quantify the additional negative effects of conventional radiotherapy compared to surgery alone on neurocognitive functioning and health-related quality of life (HRQOL) in patients with WHO grade I meningiomas. METHODS: Neurocognitive functioning and HRQOL (SF36, EORTC-BCM20) were assessed in consecutive patients (1999-2005) with WHO grade I meningiomas at least 1 year after surgical treatment in two centers for brain tumorpatients. Subsequently, we selected all patients who underwent surgery and conformal external beam fractioned radiotherapy (n=18) and matched these patients for age, sex, and educational level with the same number of patients who had had surgery only (n=18), as well as with the same number of healthy controls. RESULTS: No significant differences in neurocognitive functioning were found between the two meningiomapatient groups; however, even meningiomapatients who were treated with surgery only had a significantly lower neurocognitive functioning than healthy controls. Meningiomapatients who were treated with surgery and radiotherapy had significantly lower HRQOL scores than meningiomapatients who were treated with surgery only, who had HRQOL ratings comparable with healthy controls; these differences, however, disappeared after correction for the duration of disease. CONCLUSIONS: In contrast with conventional thinking, long-term neurocognitive functioning was significantly impaired in our meningiomapatients. Additional radiotherapy following surgery, however, does not have additional deleterious effects on neurocognitive outcome in these patients.
Authors: N K Aaronson; M Muller; P D Cohen; M L Essink-Bot; M Fekkes; R Sanderman; M A Sprangers; A te Velde; E Verrips Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: M Klein; J J Heimans; N K Aaronson; H M van der Ploeg; J Grit; M Muller; T J Postma; J J Mooij; R H Boerman; G N Beute; G J Ossenkoppele; G W van Imhoff; A W Dekker; J Jolles; B J Slotman; H Struikmans; M J B Taphoorn Journal: Lancet Date: 2002-11-02 Impact factor: 79.321
Authors: Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee Journal: J Neuropathol Exp Neurol Date: 2002-03 Impact factor: 3.685
Authors: Martin Klein; Nadine H J Engelberts; Henk M van der Ploeg; Dorotheé G A Kasteleijn-Nolst Trenité; Neil K Aaronson; Martin J B Taphoorn; Hans Baaijen; W Peter Vandertop; Martin Muller; Tjeerd J Postma; Jan J Heimans Journal: Ann Neurol Date: 2003-10 Impact factor: 10.422
Authors: Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers Journal: Neuro Oncol Date: 2012-03-09 Impact factor: 12.300
Authors: Farshad Nassiri; Benjamin Price; Ameer Shehab; Karolyn Au; Michael D Cusimano; Michael D Jenkinson; Christine Jungk; Alireza Mansouri; Thomas Santarius; Suganth Suppiah; Ken X Teng; Gurvinder S Toor; Gelareh Zadeh; Tobias Walbert; Katharine J Drummond Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: D Zlotnick; S N Kalkanis; A Quinones-Hinojosa; K Chung; M E Linskey; R L Jensen; F DeMonte; F G Barker; C A Racine; M S Berger; P M Black; M Cusimano; L N Sekhar; A Parsa; M Aghi; Michael W McDermott Journal: J Neurooncol Date: 2010-09-18 Impact factor: 4.130
Authors: Sarah K Lageman; Jane H Cerhan; Dona E C Locke; S Keith Anderson; Wenting Wu; Paul D Brown Journal: J Neurooncol Date: 2009-07-19 Impact factor: 4.130